The FDA last week approved Johnson & Johnson’s Imbruvica for the treatment of chronic graft-versus-host disease (cGVHD) in pediatric patients following the failure of at least one prior treatment. This is the first pediatric nod for the kinase inhibitor. Imbruvica became the first FDA-approved cGVHD therapy in August 2017. For that indication, it holds covered or better status for virtually all (99%) of insured lives under the pharmacy benefit. 16.5% of insured lives have preferred access to Imbruvica, growing to 42.9% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 8/29/22